The round, backed by AmorePacific's corporate venturing unit, will support the clinical advancement of Elastagen's cosmetic surgery technology.

Australia-based dermatology technology developer Elastagen has closed a A$13m ($9.1m) series B round that included funding from AmorePacific Ventures, the corporate venturing fund owned by Korea-based beauty company AmorePacific.

The round also included Korea Investment Partners, Wellcome Trust, Brandon Capital Partners, GBS Ventures and ATP Innovations.

Elastagen is developing a tropoelastin platform that can be used for cosmetic surgery on atrophic scars like stretch marks and acne scars, as well as dermaesthetics and tissue repair. The funding will help advance…

Subscribe to go deeper

GCV subscribers get access to all our proprietary data and deep-dive articles, as well as the global directory of CVC investors.



Not sure if you have a subscription?